We next investigated whether treatment of tumour-bearing mice with a neutralising anti-mouse IL-33 antibody (3 μg/mouse delivered once a week) had an impact on tumour growth and the immune compartment (Fig. 3a). The gene discussed is IL33; the disease is neoplasm.